Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort vs Monocomponents in Asthma (SPRUCE 80/4.5)
NCT00651651Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2002
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of budesonide in asthma (3 arms), sponsored by AstraZeneca. Primary endpoints: Serial FEV1 measurements at 12 weeks and Withdrawals due to asthma exacerbation at 12 weeks. Started Aug 2002; status: completed.
02
Drugs
budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00651651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00651651.